ReviewXenotransplantation
Xenotransplantation Literature Update: July-December 2025.
Review in Xenotransplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The second half of 2025 marked a significant transition for xenotransplantation, shifting further from experimental feasibility to early clinical translation. Prolonged physiologic support from genetically engineered porcine kidneys and livers in human recipients provided unprecedented insight into organ compatibility, rejection dynamics, and species-specific physiology. Parallel advances in molecular profiling refined the understanding of innate and humoral immune injury, while innovations in donor-pig engineering, immunomodulation, and biosafety frameworks strengthened translational readiness. Preclinical non-human primate studies continued to inform clinical trial design, particularly regarding proteinuria, complement incompatibility, and novel xenoantigens. Alongside these scientific advances, growing attention to ethics, patient selection, and public trust highlighted the societal dimensions of clinical implementation. Collectively, these developments underscore the rapid maturation of xenotransplantation and define the scientific and regulatory foundations for ongoing first-in-human trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.